Publikationsdatenbank

Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity (2021)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Palmieri, Vittoria

Ebel, Jana-Fabienne

Ngo Thi Phuong, Nhi

Klopfleisch, Robert (WE 12)

Vu, Vivian Pham

Adamczyk, Alexandra

Zöller, Julia

Riedel, Christian

Buer, Jan

Krebs, Philippe

Hansen, Wiebke

Pastille, Eva

Westendorf, Astrid M.

Quelle

Mucosal immunology : official journal of the Society for Mucosal Immunology

Bandzählung: 14

Heftzählung: 4

Seiten: 923 – 936

ISSN: 1933-0219

Sprache

Englisch

Verweise

URL (Volltext): https://www.nature.com/articles/s41385-021-00386-7

DOI: 10.1038/s41385-021-00386-7

Pubmed: 33654214

Kontakt

Institut für Tierpathologie

Robert-von-Ostertag-Str. 15
14163 Berlin
+49 30 838 62450
pathologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

A wide range of microbial pathogens is capable of entering the gastrointestinal tract, causing infectious diarrhea and colitis. A finely tuned balance between different cytokines is necessary to eradicate the microbial threat and to avoid infection complications. The current study identified IL-33 as a critical regulator of the immune response to the enteric pathogen Citrobacter rodentium. We observed that deficiency of the IL-33 signaling pathway attenuates bacterial-induced colitis. Conversely, boosting this pathway strongly aggravates the inflammatory response and makes the mice prone to systemic infection. Mechanistically, IL-33 mediates its detrimental effect by enhancing gut permeability and by limiting the induction of protective T helper 17 cells at the site of infection, thus impairing host defense mechanisms against the enteric pathogen. Importantly, IL-33-treated infected mice supplemented with IL-17A are able to resist the otherwise strong systemic spreading of the pathogen. These findings reveal a novel IL-33/IL-17A crosstalk that controls the pathogenesis of Citrobacter rodentium-driven infectious colitis. Manipulating the dynamics of cytokines may offer new therapeutic strategies to treat specific intestinal infections.